Medicare Advantage (MA) plans will see a 2.53% increase in payments in 2020; the FDA is developing a framework for regulatory oversight of artificial intelligence (AI); a federal court is allowing Wisconsin to withdraw 2 lawsuits from the state challenging the Affordable Care Act (ACA).
CMS has finalized a 2.53% increase in payments to Medicare Advantage (MA) plans for 2020, which they said is a reflection of a new estimate on cost growth. This is up from the 1.59% increase proposed by the agency in February, reported Reuters. The increase comes after a final estimate determined a growth rate of 5.62%, up from the 4.59% estimated in February. In 2020, MA plans will also be able to offer benefits that address beneficiaries’ social needs, such as structural changes to the home like adding ramps and widening doorways.
The FDA has released a proposed framework for tailored regulatory oversight of artificial intelligence (AI) in healthcare. According to the white paper, the agency is aiming for a framework that is based on the International Medical Device Regulators Forum risk categorization principles, FDA’s benefit—risk framework, risk management principles in the software modification guidance, and an organization-based total product lifecycle approach. The goal, according to the FDA, is to embrace AI and machine learning while also ensuring patient safety.A federal court is allowing Wisconsin’s Democratic Attorney General Josh Kaul to withdraw 2 lawsuits from the state challenging the Affordable Care Act (ACA). The first is a multistate lawsuit that resulted in a federal judge striking down the ACA, and the second is a separate multistate challenge. According to the Wisconsin State Journal, Kaul had submitted requests to remove the state from the lawsuits earlier this month following authority from a state judge.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Study Suggests Postdischarge Care Needs Targeted, Multifaceted Approaches
January 15th 2025The findings challenge the effectiveness of these widely used transitional care interventions and suggest a need for more targeted, multifaceted approaches to address the needs of higher-risk patients.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen